Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Valeant Expects to Hit Forecast

By R&D Editors | June 22, 2012

NEW YORK (AP) – Canadian drugmaker Valeant Pharmaceuticals International Inc. announced that it expects to reach the high end of its profit and revenue forecasts for the year.

During an investor presentation, Valeant said it expects to reach the high end of its previous outlook. The company now projects an adjusted profit of $4.45 and $4.70 per share and revenue of $3.4 billion to $3.6 billion. Those estimates do not include several acquisitions Valeant recently completed, or deals that have been announced but have not yet closed.

Analysts had been forecasting income of $4.46 per share and revenue of $3.5 billion on average, according to FactSet.

Valeant has announced about a dozen acquisitions this year. It has expanded its business in Russia, Eastern Europe, Latin America, and Southeast Asia through acquisitions, as well as through partnerships with companies like Gerot Lannach of Austria. Earlier this year it paid $425 million to buy Dermik, the dermatology business of French drugmaker Sanofi.

On June 15 it said it would pay about $312 million for OraPharma, which makes specialty oral health care products.

Stifel Nicolaus analyst Annabel Samimy said Valeant’s comments made it sound like analyst estimates for the second quarter are too high. Analysts expected a profit of $1.10 per share on average, and since the presentation they have cut their estimates to $1.06 per share. However Samimy continues to forecast a profit of $4.55 per share for the year and said Valeant could exceed that total.

Jefferies & Co. analyst Corey Davis said the company does a lot of business in Europe, so Valeant to affirm the upper end of financial forecast “is a testament to the strength and durability of its business model.”

Date: June 22, 2012
Source: Associated Press

Related Articles Read More >

2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE